Clinical and histopathological characteristics of familial prostate cancer in Finland

BJU International

Volumn 109, Issue 4, 2012, Pages 557-563

  Pakkanen, Sanna ^a,b   Kujala, Paula M ^b   Ha, Nati ^a,b   Matikainen, Mika P ^b,c   Schleutker, Johanna ^a,b   Tammela, Teuvo L J ^b,c  

^a UNIVERSITY OF TAMPERE   (Finland)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

^c TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

Author keywords

clinical; descriptive; familial; prostate cancer

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER SCREENING; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; FAMILIAL CANCER; FAMILY HISTORY; FINLAND; FOLLOW UP; GENETIC SCREENING; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER;

ADULT; AGE OF ONSET; AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; CASE-CONTROL STUDIES; FINLAND; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; ORCHIECTOMY; PEDIGREE; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 84857033707     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2011.10198.x     Document Type: Article

References (34)

1. Finnish Cancer Registry. Cancer incidence and mortality in Finland. Cancer statistics. Available at: (accessed August 15 2010).
2. Lichtenstein P, Holm NV, Verkasalo PK, et al,. Environmental and heritable factors in the causation of cancer-analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 2000; 343: 78-85 (Pubitemid 30451850)
3. Ostrander EA, Johannesson B,. Prostate cancer susceptibility loci: finding the genes. Adv Exp Med Biol 2008; 617: 179-90
4. Carpten J, Nupponen N, Isaacs S, et al,. Germline mutations in the ribonuclease L gene in families showing linkage with HPC1. Nat Genet 2002; 30: 181-4
5. Tavtigian SV, Simard J, Teng DH, et al,. A candidate prostate cancer susceptibility gene at chromosome 17p. Nat Genet 2001; 27: 172-80 (Pubitemid 32157444)
6. Xu J, Zheng SL, Komiya A, et al,. Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. Nat Genet 2002; 32: 321-5
7. Carter BS, Bova GS, Beaty TH, et al,. Hereditary prostate cancer: epidemiologic and clinical features. J Urol 1993; 150: 797-802 (Pubitemid 23241269)
8. Bastacky SI, Wojno KJ, Walsh PC, Carmichael MJ, Epstein JI,. Pathological features of hereditary prostate cancer. J Urol 1995; 153: 987-92
9. Bauer JJ, Srivastava S, Connelly RR, et al,. Significance of familial history of prostate cancer to traditional prognostic variables, genetic biomarkers, and recurrence after radical prostatectomy. Urology 1998; 51: 970-6 (Pubitemid 28240857)
10. Norrish AE, McRae CU, Cohen RJ, Jackson RT,. A population-based study of clinical and pathological prognostic characteristics of men with familial and sporadic prostate cancer. BJU Int 1999; 84: 311-5 (Pubitemid 29376180)
11. Valeri A, Azzouzi R, Drelon E, et al,. Early-onset hereditary prostate cancer is not associated with specific clinical and biological features. Prostate 2000; 45: 66-71
12. Bratt O,. Hereditary prostate cancer: clinical aspects. J Urol 2002; 168: 906-13
13. Roehl KA, Loeb S, Antenor JA, Corbin N, Catalona WJ,. Characteristics of patients with familial versus sporadic prostate cancer. J Urol 2006; 176: 2438-42 (Pubitemid 44755061)
14. Kupelian PA, Kupelian VA, Witte JS, Macklis R, Klein EA,. Family history of prostate cancer in patients with localized prostate cancer: an independent predictor of treatment outcome. J Clin Oncol 1997; 15: 1478-80 (Pubitemid 27167383)
15. Kupelian PA, Klein EA, Witte JS, Kupelian VA, Suh JH,. Familial prostate cancer: a different disease? J Urol 1997; 158: 2197-201 (Pubitemid 27481356)
16. Spangler E, Zeigler-Johnson CM, Malkowicz SB, Wein AJ, Rebbeck TR,. Association of prostate cancer family history with histopathological and clinical characteristics of prostate tumors. Int J Cancer 2005; 113: 471-4 (Pubitemid 40038717)
17. Bratt O, Kristoffersson U, Olsson H, Lundgren R,. Clinical course of early onset prostate cancer with special reference to family history as a prognostic factor. Eur Urol 1998; 34: 19-24 (Pubitemid 28330330)
18. Bova GS, Partin AW, Isaacs SD, et al,. Biological aggressiveness of hereditary prostate cancer: long-term evaluation following radical prostatectomy. J Urol 1998; 160: 660-3 (Pubitemid 29479482)
19. Siddiqui SA, Sengupta S, Slezak JM, Bergstralh EJ, Zincke H, Blute ML,. Impact of familial and hereditary prostate cancer on cancer specific survival after radical retropubic prostatectomy. J Urol 2006; 176: 1118-21 (Pubitemid 44142572)
20. Gleason DF,. Classification of prostatic carcinomas. Cancer Chemother Rep 1966; 50: 125-8
21. Epstein JI,. An update of the Gleason grading system. J Urol 2010; 183: 433-40
22. Epstein JI, Allsbrook WC, Amin MB, LL E, Grading ISUP Committee. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol 2005; 29: 1228-42 (Pubitemid 41232997)
23. de la Chapelle A,. Disease gene mapping in isolated human populations: the example of Finland. J Med Genet 1993; 30: 857-65
24. Teppo L, Pukkala E, Lehtonen M,. Data quality and quality control of a population-based cancer registry. Experience in Finland. Acta Oncol 1994; 33: 365-9 (Pubitemid 24207996)
25. Matikainen MP, Sankila R, Schleutker J, Kallioniemi OP, Pukkala E,. Nationwide cancer family ascertainment using Finnish cancer registry data on family names and places of birth for 35,761 prostate cancer patients. Int J Cancer 2000; 88: 307-12
26. Pakkanen S, Pukkala E, Kainulainen H, et al,. Incidence of cancer in finnish families with clinically aggressive and nonaggressive prostate cancer. Cancer Epidemiol Biomarkers Prev 2009; 18: 3049-56
27. Eble JN, Sauter G, Epstein JI, Sesterhenn IA, eds. Tumours of the Urinary System and Male Genital Organs. Geneva: World Health Organization, 2004
28. Ahaghotu C, Baffoe-Bonnie A, Kittles R, et al,. Clinical characteristics of African-American men with hereditary prostate cancer: the AAHPC Study. Prostate Cancer Prostatic Dis 2004; 7: 165-9 (Pubitemid 38931441)
29. Keetch DW, Humphrey PA, Smith DS, Stahl D, Catalona WJ,. Clinical and pathological features of hereditary prostate cancer. J Urol 1996; 155: 1841-3 (Pubitemid 26144067)
30. Ploussard G, Azancot V, Nicolaiew N, et al,. The effect of prostate-specific antigen screening during the last decade: development of clinicopathological variables independently of the biopsy core number. BJU Int 2010; 106: 1293-7
31. Grönberg H, Isaacs SD, Smith JR, et al,. Characteristics of prostate cancer in families potentially linked to the hereditary prostate cancer 1 (HPC1) locus. JAMA 1997; 278: 1251-5 (Pubitemid 27435612)
32. Bratt O, Damber J-E, Emanuelsson M, Grönberg H,. Hereditary prostate cancer: clinical characteristics and survival. J Urol 2002; 167: 2423-26 (Pubitemid 34533138)
33. Grönberg H, Damber L, Damber JE,. Familial prostate cancer in Sweden. A nationwide register cohort study. Cancer 1996; 77: 138-43 (Pubitemid 26002749)
34. Matikainen MP, Pukkala E, Schleutker J, et al,. Relatives of prostate cancer patients have an increased risk of prostate and stomach cancers: a population-based, cancer registry study in Finland. Cancer Causes Control 2001; 12: 223-30 (Pubitemid 32515369)